Celltrion disclosed that it has signed a license-in agreement for KG013, a long-acting anti-APRIL antibody with half-life extension technology, under October 22, 2026.

Celltrion disclosed that on October 22, 2026 it signed an agreement to license in KG013, a long-acting anti-APRIL antibody with half-life extension technology, from Kaigene, Inc. of the United States. The company put the total contract value at up to $580,500,000 (about KRW 769.5 billion) and said actual payments may vary depending on the development process. The company also said the agreement is conditional and may be terminated depending on clinical and marketing approval results.

1. 01

   The agreement covers KG013, a 2nd-generation antibody drug candidate aimed at treating immune diseases including IgA nephropathy. The company said the candidate features an APRIL targeting mechanism and improved persistence in the body.

2. 02

   The total contract value is up to $580,500,000, and payments may vary depending on the development process. The amount includes upfront payments, milestones and other payments.

3. 03

   The agreement is conditional. Expense recognition may differ depending on whether clinical trials and marketing approval succeed, and the agreement may be terminated if regulatory authorities take action or if marketing approval fails.

4. 04

   The company said that if the agreement is terminated early, it has no obligation to pay a penalty. Apart from the upfront payment, milestones and royalties may not be paid depending on whether they are achieved.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Counterparty

Kaigene, Inc. (United States)

Contract value (maximum)

$580,500,000 (about KRW 769.5 billion)

Contract signing date

October 22, 2026

Exchange rate basis for KRW conversion

USD/KRW 1325.50 (first market average rate on October 22, 2026)

Disclosure deferral deadline

February 15, 2047

Filing facts

Filing type

Material Management Information

Report name

Material Management Information for Investment Decisions

Filed

Oct 22, 2026

Receipt number

20261022800167